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DERIVATIVES OF MITHRAMYCIN AND 
METHODS OF MAKING AND USES 
THEREOF 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the bene?t of priority of Provi 
sional Application No. 60/548,175, ?led Mar. 1, 2004 Which 
is incorporated herein by reference. 
STATEMENT OF US. GOVERNMENT 
SPONSORED RESEARCH 
A portion of this invention Was made With U. S. government 
support under a grant from the National Institutes of Health 
(NIH), Grant No. RO1CA91901. The government may have 
certain rights in this invention. 
Mithramycin (MTM) is an aureolic acid-type polyketide 
produced by various soil bacteria of the genus Slreplomyces, 
including Slreplomyces argillaceus ATCC 12956 (deposited 
With ATCC, PO. Box 1549, Manassas, Va. 20108 USA). 
MTM has the folloWing formula (I): 
CH3 CH3 
0 0 
HO HO HO m  
B A 
HO 
CH3 CH3 CH3 
0 o 0 
HO 
HO H3C o o 
E D 0 
OH 
MTM is the most important representative of the aureolic acid 
group of antitumor agents, and is used to treat testicular 
carcinoma, Paget’s disease and hypercalcemia caused by 
malignancy-associated bone lesions. MTM is also an agent 
for neuroprotection in the treatment of neurological diseases 
such as stroke, amyotropic lateral sclerosis, Parkinson’s dis 
ease, Huntington’s disease, multiple sclerosis and viral 
encephalitis. 
The aureolic acid group of compounds includes MTM, 
chromomycin A3 (CHR), olivomycin A (OLI), UCH9, and 
durhamycin A. All contain the same tricyclic core moiety 
With a unique dihydroxy-methoxy-oxo-pentyl side chain 
attached at carbon 3 and vary only slightly, With respect to the 
residue at carbon 7, Which is either a H atom or a small alkyl 
side chain. HoWever, these naturally occurring aureolic acid 
antibiotics differ in the nature and linking of their saccharide 
chains, Which consist of various 2,6-dideoxysugar residues. 
Such structural variations impart subtle differences in the 
DNA binding and activity pro?les among the members of this 
group. 
The biosynthetic gene cluster leading to the formation of 
MTM has been studied and resulted in the identi?cation of 34 
genes and the assignment of various gene product functions 
for the biosynthesis of MTM. FIG. 1 shoWs the gene organi 
Zation of the MTM biosynthetic gene cluster in Slreplomyces 
argillaceus. MTM biosynthesis proceeds through tetracyclic 
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intermediates With glycosylation steps occurring on the tet 
racyclic biosynthetic intermediates. One of the last steps, the 
key step in MTM biosynthesis, is the oxidative cleavage of the 
fourth ring of the fully glycosylated tetracyclic intermediate 
premithramycin B, Which results in the formation of a tricy 
clic immediate precursor of MTM. FIG. 2 shoWs the rear 
rangement of the tetracyclic structure into the tricyclic struc 
ture found in MTM. This rearrangement is very important 
step because it causes an alteration of the shaping of the 
molecule. Only the tricyclic structure is biologically active. In 
conjunction With the oxidative cleavage step is a decarboxy 
lation step that occurs. A pentyl side chain attached at carbon 
3 is generated, Which plays an important role for the biologi 
cal activity of the aureolic acid class of antitumor agents. To 
generate the ?nal MTM molecule, the oxidative cleavage step 
is folloWed by a ketoreduction step, in Which the keto group in 
the 4'-position of the 3-side chain is reduced to a secondary 
alcohol. 
The present invention provides for a mutant Slreplomyces 
argillaceus (S. argillaceus M7W1) lacking a nucleic acid that 
encodes an active ketoreductase. The mutant S. argillaceus 
M7W1 produces mutant derivatives: demycaro syl-mithra 
mycin-SK, mithramycin-SA, mithramycin-SDK and mithra 
(1) 
CH3 
mycin-SK, the latter being the major product. The derivatives 
are antitumor agents and also act as neuroprotective agents in 
the treatment of neurological diseases. 
SUMMARY OF THE INVENTION 
The invention generally relates to the production of mith 
ramycin derivatives from a mutant S. argillaceus M7W 1, 
lacking a nucleic acid that encodes an active ketoreductase. 
The present invention also provides for a mutant S. argilla 
ceus M7W1 produced by mutating an mtmW gene of Strep 
lomyces argillaceus, Whereby the mutated gene does not 
encode active ketoreductase. 
The present invention further provides a method of making 
a mutant S. argillaceus M7W1 comprising mutating an 
mtmW gene of S. argillaceus to produce a mutated gene by 
insertional mutation of the mtmW gene, Whereby the mutated 
gene does not encode active ketoreductase. The mtmW is 
mutated ex vivo, and is used to replace the Wild type mtmW 
gene of Slreplomyces argillaceus. 
Finally, the invention relates to mutated organisms useful 
in the production of mithramycin derivatives: demycarosyl 
mithramycin-SK, mithramycin-SA, mithramycin-SDK and 
mithramycin-SK. 
Additional advantages of the invention Will be set forth in 
part in the description Which folloWs, and in part Will be 
obvious from the description, or may be learned by practice of 
US 7,423,008 B2 
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the invention. The advantages of the invention Will be realized 
and attained by means of the elements and combinations 
particularly pointed out in the appended claims. It is to be 
understood that both the foregoing general description and 
the following detailed description are exemplary and 
explanatory only and are not restrictive of the invention as 
claimed. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is the gene organization of the MTM biosynthetic 
gene cluster in Slreplomyces argillaceus. 
FIG. 2 shoWs the rearrangement of the tetracyclic rings to 
form MTM. 
FIG. 3 shoWs a non-enzymatic Favorskii-type rearrange 
ment in the formation of mithramycin SK and mithramycin 
SA. 
FIG. 4 is a schematic representation of the gene replace 
ment experiment for generating the mutant S. argillaceus 
M7Wl. 
FIG. 5 shoWs a comparison of the rearrangement of the 
tetracyclic rings in forming MTM, mithramycin-SK and 
mithramycin-SA. 
FIGS. 6A, 6B and 6C are the sequence listing for a gene 
containing aac(3)IV and mtmW genes (SEQ ID NO: 1). 
DETAILED DESCRIPTION OF THE INVENTION 
The present invention may be understood more readily by 
reference to the folloWing detailed description of preferred 
embodiments of the invention and the examples included 
therein and to the draWing ?gures and their previous and 
folloWing description. As used in the speci?cation and the 
appended claims, the singular forms “a,” “an” and “the” 
include plural referents unless the context clearly dictates 
otherWise. Thus, for example, reference to “a pharmaceuti 
cally acceptable carrier” includes mixtures of tWo or more 
such carriers, and the like. 
The gene replacement step of the present invention 
involves standard nucleic acid manipulations Well knoWn to 
the skilled artisan. “Nucleic acid” as used herein refers to 
single- or double-stranded molecules Which may be DNA, 
comprised of the nucleotide bases A, T, C and G, or RNA, 
comprised of the bases A, U (substitutes for T), C, and G. The 
nucleic acid may represent a coding strand or its complement. 
Nucleic acids may be identical in sequence to the sequence 
Which is naturally occurring or may include alternative 
codons Which encode the same amino acid as that Which is 
found in the naturally occurring sequence. Furthermore, 
nucleic acids may include codons Which represent conserva 
tive substitutions of amino acids as are Well knoWn in the art. 
The isolation of nucleic acids can therefore be accom 
plished by techniques such as cell lysis folloWed by phenol 
plus chloroform extraction, folloWed by ethanol precipitation 
of the nucleic acids. The nucleic acids of this invention can be 
isolated from bacterial cells, for example, Slreplomyces 
argillaceus, according to methods Well knoWn in the art for 
isolating nucleic acids. Alternatively, the nucleic acids of the 
present invention can be synthesized according to standard 
protocols Well described in the literature for synthesizing 
nucleic acids. Modi?cations to the nucleic acids of the inven 
tion, for example, the mtmW gene Which encodes an active 
ketoreductase, Will decrease the activity of the enzyme or 
block or reduce its synthesis. 
A nucleic acid containing a promoter or other regulatory 
sequence and/ or encoding a protein (e.g., antibiotic resistance 
factor or enzyme) of this invention can be part of a recombi 
nant nucleic acid construct comprising any combination of 
restriction sites and/or functional elements as are Well knoWn 
in the art Which facilitate molecular cloning and other recom 
binant DNA manipulations. Thus, the present invention fur 
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ther provides a recombinant nucleic acid construct compris 
ing a nucleic acid encoding an enzyme to be modi?ed or 
deleted by this invention. 
The nucleic acid sequences can be expressed in hosts, for 
example, Slreplomyces argillaceus, after the sequences have 
been positioned to ensure the functioning of an expression 
control sequence. Ho st cells of the present invention are trans 
formed and cultured in conventional nutrient media modi?ed 
as appropriate for inducing the various promoters if induction 
is carried out. “Transformation” means introducing DNA into 
an organism so that the DNA is replicable, either as an extra 
chromosomal element or as chromosomal integration. 
Depending on the host cell used, transformation is done using 
standard techniques appropriate to such cells. 
A “cell” can be a cell from any organism including, but not 
limited to, a bacterium. Bacterial cells of this invention are 
cultured in suitable media in Which the promoters can be 
induced using standard techniques. Any other necessary 
supplements besides carbon, nitrogen, and inorganic phos 
phate sources may also be included at appropriate concentra 
tions, introduced alone or as a mixture With another supple 
ment or medium such as a complex nitrogen source. 
The present invention provides a method of inhibiting 
groWth of a tumor, comprising contacting the tumor With a 
compound of the invention. As used herein, “inhibiting” 
means decreasing, sloWing or stopping. Thus, a compound of 
this invention can decrease, sloW or stop the groWth of a tumor 
cell. As used herein, “groWt ” means increase in size or 
proliferation or both. Thus, a compound of this invention can 
inhibit a tumor cell from becoming larger and/ or can prevent 
the tumor cell from dividing and replicating and increasing 
the number of tumor cells. A “tumor cell” is a cell comprising 
a neoplasm (neW groWth), Which can be cancerous (malig 
nant) or non-cancerous (benign). A cancerous tumor cell can 
invade surrounding normal tissues and blood/lymph vessels 
and metastasize to tissues distant from the original tumor. In 
contrast, a non-cancerous tumor cell can groW and compress 
surrounding normal tissue but cannot invade normal tissues 
and blood/lymph vessels nor metastasize to tissues distant 
from the original tumor. 
A cell can be in vitro.Altematively, a cell canbe in vivo and 
can be found in a subject. A “cell” can be a cell from any 
organism including, but not limited to, abacterium. As used 
throughout, the “subject” can include domesticated animals, 
such as cats, dogs, etc., livestock (e.g., cattle, horses, pigs, 
sheep, goats, etc.), laboratory animals (e.g., mouse, rabbit, 
rat, guinea pig, etc.) and birds. Preferably, the subject is a 
mammal such as a primate, and, more preferably, a human. 
The present invention provides a method of treating cancer 
in a subject diagnosed With cancer, comprising administering 
to the subject an effective amount of a compound of the 
invention in a pharmaceutically acceptable carrier, Whereby 
the compound treats the cancer in the subject. In general, an 
“effective amount” of a compound is that amount needed to 
achieve the desired result or results. For example, an effective 
amount of a compound of the present invention treats the 
cancer by inhibiting the groWth of the cells comprising the 
tumor, thereby preventing invasion of normal tissues and 
blood/lymph vessels by the tumor cells, thus preventing 
metastases. Examples of cancers that can be treated include, 
but are not limited to, lung, colon, ovarian, prostate, testicular, 
melanoma, kidney, breast, central nervous system and leuke 
mia. By “pharmaceutically acceptable” is meant a material 
that is not biologically or otherWise undesirable, i.e., the 
material may be administered to an individual along With the 
selected compound Without causing substantial deleterious 
biological effects or interacting in a deleterious manner With 
any of the other components of the composition in Which it is 
contained. 
The invention is directed to modifying the post-polyketide 
synthase (post-PKS) tailoring steps of the mithramycin bio 
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synthesis by Slreplomyces argillaceus, in particular, the 
ketoreductase encoding genes. The ketoreductase step Within 
the pentyl side chain attached at carbon 3 to MTM side chain 
is the last step of the mithramycin biosynthesis. The mtmW 
gene is the enzyme that catalyzes the ketoreduction step 
affecting the 3-side chain in the mithramycin biosynthesis. 
The mtmW gene is located ca. 8 kb downstream of the 
mithramycin PKS genes. The gene is replaced by an aac(3)lV 
gene that yields a S. argillaceus mutant, Which produces four 
neW mithramycin derivatives, namely mithramycin-SK, 
demycaro syl-mithramycin-SK, mithramycin- SA, mithramy 
cin-SDK. Mithramycin-SK is the major product. The struc 
tures of mithramycin- SK and demycaro syl-mithramycin- SK 
bear a butyl side chain attached at carbon 3 instead of the 
expected pentyl side chain With an additional keto function. 
This can be explained through a non-enZymatic Favorskii 
type rearrangement of the initially formed pentyl side chain 
With tWo keto groups in [3-position to each other. FIG. 3 shoWs 
the non-enzymatic Favorskii-type rearrangement in the for 
mation of mithramycin-SK and mithramycin-SA having 
structures 2 and 4, respectively, from MTM having structure 
5. 
The invention contemplates mutant MTM derivatives hav 
ing the folloWing general formula (H): 
CH3 CH3 
1 
R o 0 R30 0 0 
R20 0 
R12 
OR4 OR5 
R80 
CH3 
Wherein 
R1, R2, R3, R4, R5 , R6, R7 and R8 are each, independently, 
hydrogen or a protecting group; 
X is C:O or CH(ORU), wherein R11 is hydrogen or a 
protecting group; 
R10 is OH When X is C:O or C(O)CH3 When X is 
CH(ORU); 
R9 is hydrogen, a protecting group or 
CH3 
R140 
ORB 
R12 is methyl or hydrogen; and 
the stereochemistry at carbons a, b and c is R, S or mixtures 
thereof, and When X is CH(ORU), the stereochemistry 
of d is R or S. 
One or more of the hydroxyl groups present in the mutant 
derivative can be protected With a protecting group. The term 
“protecting group” is de?ned herein as a group that is used to 
replace hydrogen of a hydroxyl group to produce a neW 
group. Various protecting groups useful in the invention and 
methods for their synthesis and removal are Well knoWn in the 
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art. Examples of many of the possible groups can be found in 
“Protective Groups in Organic Synthesis” by T. W. Green, 
John Wiley and Sons, 1981, Which is incorporated herein by 
reference in its entirety. 
The protecting group comprises, but is not limited to, an 
alkyl group, a cycloalkyl group, a heterocyloalkyl group, a 
hydroxyalkyl group, a halogenated alkyl group, an alkoxy 
alkyl group, an alkenyl group, an alkynyl group, an aryl 
group, a heteroaryl group, an aralkyl group, an ester, a car 
bonate group, a carboxylic acid, an aldehyde, a keto group, an 
ether group, a urethane group, a silyl group, a sulfo-oxo 
group, or any combination thereof. In one embodiment, when 
R1 l in formula (II) is a protecting group, the protecting group 
is an alkyl group such as methyl, ethyl, propyl, isopropyl, 
butyl, isobutyl, or pentyl. In another embodiment, some the 
hydroxyl groups in formula (11) may be protected While others 
are not. For example, R1, R2, R3, R4, R , R6, R7, R8, R13 and 
R14 may be not protected While R1 1 is protected by an alkyl 
group selected from the group consisting of methyl, ethyl, 
propyl, isopropyl, butyl, isobutyl and pentyl. 
The protecting groups are removable from the product 
compounds of the invention, to regenerate the hydroxyl group 
by methods knoWn in the art. Methods for removing protect 
(11) 
R60 
ing groups include, but are not limited to, hydrolysis, hydro 
genolysis, treatment With acids or bases, and the like. 
The stereocenters a, b and c in formula (II) can be R, S or 
mixtures thereof. The term “mixtures thereof’ With respect to 
the stereochemistry of a-c, When considered With stereo 
center d, includes all possible diastereoisomers and enanti 
omers of formula (II). A compound having the formula (II) 
can be a racemic mixture or exist as an enantiomeric excess of 
a particular stereochemistry. Alternatively, a compound hav 
ing the formula (II) can exist as tWo or more diastereoisomers. 
For example, the stereochemistry at carbons a, b and c are S 
and the stereochemistry at carbon d is R or the compounds 
having the formula (II) can be enantiomerically pure. 
Using techniques known in the art, it is possible to epimer 
iZe the stereocenters a-d. A compound having the formula (II) 
can be treated With a base in order to produce a racemic or 
diastereomeric mixture. Also, the use of a chiral auxiliary in 
combination With a base can be used to selectively convert 
stereocenters a-d from one stereoisomer to the other. 
The mutant S. argillaceus M7Wl produces ?ve neW 
derivatives of MTM: mithramycin-SK, demycarosyl-mithra 
mycin-SK, mithramycin-SA and mithramycin-SDK. Mithra 
mycin-SK has the folloWing formula (III): 
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CH3 
CH3 CH3 CH3 
HO H3C O O 
OH 
In a preferred embodiment, the stereochemistry at carbons a, 20 
b and c is S and the stereochemistry at d is either R or S. The 
methyl group on the ?rst aromatic ring of mithramycin-SK 
can be a H, thereby providing another derivative of formula 
(III). 
Demycarosyl-mithramycin-SK has the following formula 25 
(IV): 
(1V) 
CH3 
HO HO 
CH3 
0H 
CH3 CH3 
HO 
HO O 
Mithramycin-SA has the folloWing formula (V): 
50 
(V) 
OH 60 
CH3 CH3 CH3 
HO 
OH 65 
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Mithramycin-SDK has the following formula (V I): 
10 
(V1) 
CH3 
CH3 0 
HO H3C 
OH 
The method for making and isolating derivatives mithra 
mycin-SK, mithramycin-SA, demycarosyl-mithramycin 
SK, and mithramycin-SDK, generally involves (i) incubating 
the mutant S. argillaceus M7W1, (ii) forming a composition 
and (iii) isolating the derivatives from the composition. The 
incubation time and temperature Will vary depending upon 
the amount of mutant that is employed. The incubation tem 
perature is generally from 25° C. to 40° C., from 30° C. to 35° 
C., and preferably 30° C. The incubation time ranges from 
generally several hours to several days, e.g., from 1 to 10 
days, 2 to 9 days, 3 to 8 days, 4 to 7 days, and 5 to 6 days. 
The mutant S. argillaceus M7W1 is generally incubated in 
a solution. An example of a solution useful includes, but is not 
limited to, a broth containing the minimal factors required for 
S. argillaceus M7W1 survival or groWth. After incubation, 
the composition is centrifuged, and the supernatant is applied 
to a solid-phase extraction cartridge to isolate the derivatives. 
The derivatives can be further puri?ed using techniques 
knoWn in the art. 
Generation of the Mutant S. argillaceus by Gene 
Replacement 
The mutant S. argillaceus M7W1 is prepared in the folloW 
ing manner. Slreplomyces argillaceus ATCC 12956 Was used 
as the source of chromosomal DNA. For sporulation on a 
solid medium, it Was groWn at 30° C. on plates containing 
medium A. For protoplast transformation, it Was groWn in a 
YEME medium containing 17% sucrose. For groWth in a 
liquidmedium, Slreplomyces argillaceus Was groWn in a TSB 
medium (trypticase soya broth, Oxoid). Escherichia coli 
XLlblue Was used as the host for plasmid propagation. Meth 
ods of preparation and transformation of Slreplomyces 
argillaceus protoplasts are taught by T. Kieser et al., in “Prac 
tical Slreplomyces Genetics,” published in 2000 by the John 
Ines Foundation of NorWich, England. This reference is 
incorporated herein in its entirety. 
When plasmid-containing clones Were groWn, the medium 
Was supplemented With the appropriate antibiotics: thiostrep 
30 
35 
40 
45 
50 
55 
60 
65 
ton, 25 ug/mL; tobramycin, 20 ug/mL; ampicillin, 100 
ug/mL; or apramycin, 25 ug/mL. Plasmids pBSKT, pl] 2921, 
plAGO, and pEFBA Were used (the pEFBA plasmid is a 
pBSK derivative containing an apramycin resistance cassette; 
pBSK can be obtained from Stratagene, 11011 M. Torrey 
Pines Road, La Jolla, Calif.). Plasmid DNA preparations, 
restriction endonuclease digestions, alkaline phosphatase 
treatments, ligations, Southern hybridiZation, and other DNA 
manipulations Were performed according to standard proce 
dures for E. coli and Slreplomyces. 
DNA sequencing Was performed on double- stranded DNA 
templates using the dideoxynucleotide chain-termination 
method. Both DNA strands Were sequenced With primers 
supplied in the kits or With internal oligoprimers (17-mer) 
using anALF-express automatic DNA sequencer (Pharmacia 
Biotech). Computer-aided database searching and sequence 
analyses Were conducted using the University of Wisconsin 
Genetics Computer Group programs package (U WGCG) and 
the BLAST program. 
A schematic representation of the gene replacement pro 
cedure generating mutant S. argillaceus M7W1 is shoWn in 
FIG. 4. The 1.4 kb region of the mtmW gene is located 
betWeen several sugar biosynthetic genes (mtmV, mtmU, 
mtmC, and mtmTSl) and glycosyltransferase genes (mtm 
GIV and mtmGlll). The sequence of the mtmW gene has been 
deposited at the EMBL bank (European Molecular Biology 
Laboratory, Meyerhof Strasse 1, 69117 Heidelberg, Ger 
many) on Apr. 29, 2002, With the accession number 
AJ459240. 
The mtmW gene is comprised of 981 nucleotides With a 
GTG start codon and a TAG stop codon and codes for a 
polypeptide of 326 amino acids With an estimated Mr of 35 
304. This codon region shoWs the high GC content and bias 
for the third codon position, Which is characteristic of Strep 
lomyces genes. Comparison of the deduced product of mtmW 
With other proteins using protein databases revealed similari 
ties With various oxidoreductases. The highest similarities 
Were observed With a putative potassium channel beta subunit 
of Deinococcus radiodurans (40% identical amino acids). It 
also shoWed similarity With the EryBll (33% identical amino 
US 7,423,008 B2 
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acids) and TyICII (33% identical amino acids) proteins. 
These tWo proteins are oxidoreductases, Which participate in 
deoxygenation steps during the biosynthesis of the deoxysug 
ars that form part of the macrolide antibiotics erythromycin 
and tylosin, respectively. 
The mtmW is inactivated by gene replacement through the 
insertion of an apramycin resistance cassette. To inactivate 
the mtmW gene, a 4.5 kb BamHI fragment containing 
mtmW, mtmGlV, and portions of adjacent genes is subcloned 
into the BamHI site of pBSKT, generating M7W0. Upon 
transformation of the Wild-type Slreplomyces argillaceus 
ATCC 12956 With pM7W1, transformants Were selected for 
their resistance to apramycin. An apramycin resistance cas 
sette containing the aac(3)IV gene Was subcloned as a 1.5 kb 
SmaI-EcoRV fragment into the unique Bg/II site (blunt 
ended) located Within the coding region for mtmW and ori 
ented in the direction of transcription of mtmW, thus gener 
ating mutant S. argillaceus M7Wl. 
The aac(3)IV gene is deposited at Gen Bank having acces 
sion numbers X01385 and V01499. The sequence listing 
containing the aac(3)IV and mtmW genes is set forth in FIG. 
6 as SEQ ID NO: 1. Nucleotides 1416 to 4221 of SEQ ID 
N011 represent the mutated mtmW gene While nucleotides 
2104-3608 of SEQ ID NO:1 represent the aac(3)IV cassette. 
This construct, pM7W1, Was used to transform protoplasts of 
Slreplomyces argillaceus, and these transformants Were 
selected for resistance to apramycin. Any antibiotic resistance 
gene can be used provided that it can be selected for resistance 
in Slreplomyces argillaceus. Examples include, but are not 
limited to, erythromycin, hygromycin, thiostrepton, specti 
nomycin, viomycin and kanamycin. 
To verify that gene replacement occurred, the transfor 
mants Were tested for their susceptibility to thiostrepton. The 
Wild-type region of the chromosome Was replaced by the in 
vitro mutant S. argillaceus M7W1 through a double crossover 
at both sides of the apramycin cassette. The mutant S. argilla 
ceus M7W1 is sensitive to thiostrepton, the consequence of a 
double crossover, Which results in the replacement of the 
Wild-type gene by the in vitro mutated one. This fact Was 
con?rmed by Southern hybridiZation: the 4.5 kb BamHl frag 
ment of the Wild-type strain Was replaced by tWo neW BamW 
fragments of 3.7 and 2.3 kb, as expected if the replacement 
occurred. It Was also con?rmed that the gene replacement 
only affected mtmW, because expressing this gene in trans, 
using pAGW, restored MTM production in mutant S. argilla 
ceus M7Wl. 
Production and Isolation of Mithramycin-SK, 
Mithramycin-SA and Demycarosyl-Mithramycin-SK 
The derivatives mithramycin-SK, mithramycin-SA and 
demycarosyl-mithramycin-SK Were prepared in the folloW 
ing manner. A seed culture Was prepared using TSB inocu 
lated With spores of S. argillaceus M7W1 and incubated in an 
orbital shaker for 24 hours at 30° C. and 250 rpm. This seed 
culture Was used to inoculate (at 2.5% v/v) eight 2-liter Erlen 
meyer ?asks, each containing 400 mL of R5A medium. The 
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?asks Were incubated for 5 days under the previously 
described conditions. The entire culture obtained Was centri 
fuged (12,000 rpm, 30 minutes), the pellets Were discarded, 
and the supernatant Was ?ltered using membrane ?lters With 
a pore siZe of 0.45 pm. The ?ltrate Was applied to a solid 
phase extraction cartridge (Supelclean LC-18, 10 g, Supeico), 
and the retained material Was eluted With a mixture of metha 
nol and Water. A linear gradient from 0% to 100% methanol 
over 60 min, at 10 mL/min, Was used. 
Fractions Were taken every 5 minutes. The neW derivatives 
Were found in fractions eluted betWeen 40 and 55 minutes. 
These fractions Were evaporated under vacuum, redissolved 
in a mixture of dimethyl sulfoxide and methanol (50: 50), and 
chromatographed using a uBondapak C18 preparative col 
umn (PrepPak Cartridge, 25 mm><100 mm, Waters), With 
acetonitrile (ACN) and Water as solvents, at a ?oW rate of 10 
mL/min. A linear gradient from 30% to 50% ACN in 30 
minutes Was used. The elutant Was further puri?ed under 
isocratic conditions With 37.5% ACN in Water as a solvent. 
The isolated products Were ?nally dried in vacuo and 
Weighed. TWo compounds isolated and puri?ed Were mithra 
mycin-SK and demycarosyl-mithramycin-SK, the mithra 
mycin-SK being the major product produced. 
An alternative procedure via liquid extraction and conven 
tional chromatography yielded mithramycin-SA in addition 
to mithramycin-SK and demycarosyl-mithramycin-SK. The 
procedure is described as folloWs. A seed culture Was pre 
pared using TSB inoculated With spores of S. argillaceus 
M7W1 and incubated in an orbital shaker for 24 hours at 30° 
C. and 250 rpm. This seed culture Was used to inoculate (at 2.5 
v/v) sixteen 250-mL Erlenmeyer ?asks, each containing 100 
mL of modi?ed R5 medium. Thirty-tWo hours after the inocu 
lation, a pulse feeding of sodium acetate Was started and 
continued for 36 hours at 12 hour intervals (four feedings for 
a total of 1 g of sodium acetate per liter of culture). The culture 
Was then groWn for an additional 52 hours, for a total of 120 
hours before extraction. Following acidi?cation With HC1 to 
pH 5.5, the culture Was extracted ?rst With EtOAc and then 
With BuOH. 
The more-lipophilic compounds, mithramycin-SK (yield 
of 13.7 mg) and demycarsoyl-mithramycin-SK (yield of 3.2 
mg), Were found in the EtOAC extract, Whereas the more 
hydrophilic mithramycin-SA (yield of 4.8 mg) Was solely 
found in the n-BuOH extract. Silica gel chromatography Was 
used for both the EtOAc extract and the n-BuOH extract. 
Mithramycin-SK and demycarosyl-mithramycin-SK Were 
puri?ed using an RP-18 silica gel column, folloWed by 
Sephadex-LH 20 chromatography. Mithramycin-SA Was 
puri?ed through preparative thin-layer chromatography 
(TLC), using RP-18 silica gel plates. The exact isolation 
procedure is described Remsing et al., J. Am. Chem Soc., Vol. 
125, No. 19, pp. 5745 to 5753 Which is incorporated herein by 
reference. 
An analog of mithramycin-SK having the folloWing for 
mula (VII) can be produced from mutant S. argillaceus 
M7W1: 
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OH 
This compound can be prepared by inactivating the respec 
tive methyltransferase gene in S. argillaceus M7W1. The 
techniques inactivating the respective methyltransferase gene 
are disclosed in FemandeZ-LoZano et al. in “Characterization 
of TWo Polyketide Methyltransferases Involved in the Bio 
synthesis of the Antitumor Drug Mithramycin by Streptomy 
ces argillaceus,”.]. Biol. Chem. 200, 275, 3065-3074 (2000), 
and Remsing et al. in “Ketopremithramycins and Ketomith 
ramycins, Four NeW Aureolic Acid-Type Compounds 
Obtained upon Inactivation of TWo Genes Involved in the 
Biosynthesis of the Deoxysugar Moieties of the Antitumor 
20 
25 
14 
(V11) 
cH3 
Drug Mithramycin by Slreplomyces Argillaceus, Reveal 
Novel Insights into Post-PKS Tailoring Steps of the Mithra 
mycin Biosynthetic Pathway”, .1. Am. Chem Soc., Vol. 124, 
No. 8, 1606-1614 (2002), Which are incorporated by refer 
ence in their entireties. The methyltransferase gene S. argilla 
ceus M7W 1 can be mutated prior to or after the mutation of 
the mtmW gene S. argillaceus M7W 1. 
Mithramycin SK has a molecular formula of CSIHMO23 
and a molecular Weight of 1054.4. The 1H-NMR and 13C 
NMR data are provide in Table 1 and based on the folloWing 
labeling scheme: 
TABLE 1 
cH3 cH3 
Ho 0 Ho 0 0 
Ho 0 
B A 
1B 3A 1A 
Ho 
cH3 
OH 
lH-NMR (acetone-d6, 400 MHZ) and l3c-NMR (acetone-d6, 100 MHZ) Data 
for Mithramycin-SK 
Position 1H 6 (ppm) Multiplicity, 1 (Hz) 13C 6 (ppm) HMBC 
1 i i 203.5 
2 4.7 d (11.5) 78.18 10, 3, 4,, 4e, 1' 
3 2.48 overlap 43.71 2, 4a, 4e, 1', 2' 
4, 3.15 dd (16, 3) 28.3 2,10,1',2' 
46 2.99 overlap 28.3 
4a i i 136.9 
5 6.87 S 101.7 
6 i i 159.9 
7 i i 111.0 
7-CH3 2.15 S 7.91 
8 i i 156.2 
8a i i 108.0 
9 i i 165.3 
9a i i 108.5 
10 6.89 S 117.0 
10a i i 139.1 
1' 79.28 1'—OCH3 dd(3.4, 1.5) 
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2H, 5-H, and 10-H). l3C-NMR (125.7 MHZ, acetone-d6, 6): 
7.9 (7-CH3), 16.5 (C-6D), 17.6 (C-6B), 17.9 (C-6C and 
C-6A), 26.2 (C-4'), 28.3 (C-4), 35.2 (C-2D), 37.5 (C-2A), 
37.9 (C-2C), 40.0 (C-2B), 43.8 (C-3), 60.0 (1'-OCH3), 68.9 
(C-3D), 70.2 (C-4D), 71.3 (C-5D), 72.7 (C-5A and C-5C), 
75.4 (C-4A), 75.7 (C-4C), 77.5 (C-4B), 78.1 (C-2), 79.30 
(C-1'), 79.5 (C-2'), 81.3 (C-3A), 81.7 (C-3C), 97.1 (C-1A), 
99.9 (C-lB), 100.4 (C-1D), 100.8 (C-1C), 101.7 (C-5), 108.0 
(C-8a), 108.6 (C-9a), 111.1 (C-7), 117.1 (C-10), 137.0 
(C-4a), 139.1 (C-10a), 156.1 (C-8), 160.0 (C-6), 165.4 (C-9), 
203.6 (C-1) and 209.8 (C-3'). 
Mithramycin SA has a molecular formula of C49H7OO23 
and a molecular Weight of 1049.4, and has the 1H-NMR and 
l3C-NMR data: 1H-NMR (400 MHZ, pyridine-d5, 6): 1.50 (s, 
3H, 3E-CH3), 1.52 (d, 3H, 1:65 HZ, 6E-H3), 1.62 (d, 9H, 
1:60 HZ, 6A-H3, 6CiH3, and 6D-H3), 1.68 (d, 3H, 1:60 
HZ, 6BiH3), 1.77 (bt, 2H, 1:100 HZ, 2E-Ha, and 2BiHa), 
1.92 (bdd, 1H, 1:12, 9 HZ, 2CiHa), 2.02 (bdd, 1H, 1:12, 11 
HZ, 2D-Ha), 2.08-2.22 (overlap, 2H, 2A-Ha, and 2D-Ha, and 
2D-He), 2.28 (dd, 1H, 1:9, 2 HZ, 2E-He), 2.38 (bd, 1H, 1:10 
HZ, 2A-He), 2.47 (s, 3H, 7-CH3), 2.54 (m, 1H, 2CiHe), 2.79 
(m, 1H, 2B-Hc), 2.93(m, 1H, 4-He), 3.11 (bt, 1H, 1:152 HZ, 
4-Ha) 3.14(bt, 1H, 1:11 HZ, 3-H), 3.36 (d, W,J:9 HZ, 4E-H), 
3.49-3.72 (overlap, 4H, 3A-H, 3BiH, 3CiH, and 5A-H), 
3.55 (dd, 1H, 9, 8.5 HZ, 4CiH), 3.62 (s, 3H, 1'-OCH3), 3.84 
(bdd, 1H, 1:120, 4.5 HZ, 3D-H), 3.93-4.02 (overlap, 4H, 
4A-H, 4BiH, 4D-H, 5CiH, and 5D-H), 3.98 (dq, 1H, 
1:100, 6.0 HZ, 5E-H), 4.29 (dq, 1H, 1:100, 6.0 HZ, 5BiH), 
4.76 (bd, 1H, 1:10 HZ, lD-H), 4.86 (d, 1H, 1:15 HZ, 1'-H), 
4.92 (d, 1H, 1:11 HZ, 2-H), 5.00 (dd, 1H, 1:10, 2 HZ lBiH), 
5.41 (dd, 1H, 1:10, 2 HZ, lCiH), 5.53 (dd, 1H, 1:10, 2 HZ, 
lE-H), 5.61 (dd, 1:10, 2 HZ, lA-H), 6.61 (s, 1H, 10-H), and 
7.01 (s, 1H, 5-H). l3C-NMR (75.4 MHZ. methanol-d4, 6): 7.1 
(7-CH3),15.9 (C-6D), 17.1 (C-6B), 17.3 (C-6C), 17.4 
(C-6A), 18.0 (C-6E), 26.3 (3E-CH3), 29.7 (C-4), 32.3 
(C-2D), 37.1 (C-2A), 37.5 (C-2C), 39.7 (C-2B), 44.6 (C-2E 
and C-3), 59.6 (1'-OCH3), 68.7 (C-4D), 70.7 (C-3E and 
C-5E), 70.9 (C-3B and C-5D), 72.5 (C-5C and C-5B), 72.9 
(C-5A), 75.1 (C-4A), 75.7 (C-4C), 76.2 (C-3D), 76.8 (C-4E), 
77.0 (C-2 and C-4B), 79.5 (C-3A), 81.5 (C-3C), 82.2 (C-1'), 
97.5 (C-1A) 97.6 (C-1E), 98.8 (C-lB and C-1D), 100.0 
(C-1C), 100.1 (C-5), 108.0 (C-8a), 108.6 (C-9a), 111.7 (C-7), 
117.2 (C-10), 138.5 (C-4a), 138.7 (C-10a), 159.2 (C-6), 160.5 
(C-8), 165.0 (C-9), 176.8 (C-2') and 198.4 (C-1). 
Production and Isolation of Mithramycin SDK 
A seed culture Was prepared using TSB inoculated With 
spores of the S. argillaceus M7W1 mutant and incubated in an 
orbital shaker for 24 hours at 30° C. and 195 rpm. This seed 
culture Was used to inoculate (at 2.5%, v/v) tWenty 250 ml 
Erlenmeyer ?asks, each containing 100 ml of modi?ed R5 
media for ?ve days. The cultured media Was centrifuged at 
4,000 rpm for 30 minutes and the supernatants passed through 
a reverse phase column (45x10 cm) With pressure folloWed 
by Washing the column With acetonitrile:Water (5:95). Three 
fractions Were collected eluting With ACN:Water mixtures 
and increasing the ACN partition: fraction 1 (20% ACN) 
contains mithramycin-SA, fraction 2 (25% ACN) contains 
mithramycin-SK, and fraction 3 (31% acetonitrile) contains 
mithramycin-SDK. Fraction three (F3) Was further puri?ed 
by a reverse phase column (15x15 cm, ACN:Water 33:67), 
yielding 28.4 mg mithramycin-SDK. 
Mithramycin-SDK has a molecular formula of C5 lH72023 
and a molecular Weight of 1053.1. The 1H-NMR and 13C 
NMR data are provide in Table 2 and based on the same 
labeling scheme as for Mithramycin-SK: 
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TABLE 2 
1H-NMR (pyridine-d5, 400 MHZ) and l3c-NMR (pyridine-d5, 
100 MHZ) Data for Mithralnvcin SDK 
Multiplicity 6 13C Important 3] 
Position 6 1H (ppm) J (HZ) (ppm) HMBC 
Aglycon 
1 i 4 204.3 f 
2 4.87 d (12) 78.0 1C, 4, 9a 
3 3.09 dddd(12,12,3,1) 43.6 1, 4a, 2' 
4ax 3.27 (brdd, 16,12) 28.4 2,10,9a,1 
4eq 2.85 dd (16, 3) 2, 9a, 1' 
4a 4 4 136.6 f 
5 7.09 S 100.9 7, 8a, 10 
6 i 4 160.3 f 
7 i 4 111.5 f 
7-CH3 2.44 S 9.4 6, 8 
8 i 4 157.4 4 
8a 4 4 109.6 f 
9 i 4 166.8 4 
9a 4 4 109.6 f 
10 6.70 br. S 117.4 5, 8a, 9a, 4 
10a 4 4 139.5 f 
1' 5.49 d (1) 83.5 2, 4, 4OCH3, 
1'- 3.72 S 59.7 1' 
OCH3 
2' i 4 198.6 f 
3' i 4 199.5 f 
4' 2.42 S 26.4 2' 
SugarA ([3-D-olivose) 
1A 5.62 dd (10, 2) 98.4 6 
2Aax 2.16 ddd(12,12, 10) 37.4 
2Aeq 2.51 m (overlap) 
3A 4.54 ddd (12, 9, 5) 81.3 1B 
4A 3.43 dd (9, 9) 75.4 
5A 3.55 m (overlap) 72.6 
6A 1.56 d (6) 18.0 
Sugar B ([3-D-olivose) 
1B 5.56 dd (10, 2) 100.2 3A 
2B,X 2.04 ddd(12,12, 10) 40.0 
2Beq 2.46 m (overlap) 
3B 4.44 m (overlap) 71.4 
4B 3.33 dd (9, 9) 77.6 
SE 3.41 dq (9, 6) 72.6 
6B 1.45 d 17.7 
Sugar C ([3-D-olivose) 
1C 5.39 dd (10, 2) 100.8 2 
2C,X 1.80 ddd(12,12,10) 37.9 
2Ceq 2.95 ddd (12, 5, 2) 
3C 4.09 m (overlap) 81.8 1D 
4C 3.47 dd (9, 9) 75.7 
5C 3.65 dq (9, 6) 72.6 
6C 1.38 d (6) 17.9 
Sugar D ([3-D-oliose) 
1D 4.74 dd (10, 2) 100.3 3C 
2D,X 1.79 ddd(12,12,10) 32.5 
2Deq 2.43 ddd (12, 5, 2) 
3D 3.98 ddd (12, 5, 3) 77.3 1E 
4D 3.53 br. S 68.9 
SD 3.63 m (overlap) 71.0 
6D 1.39 d (6) 16.5 
Sugar E (?-D-macarose) 
1E 5.34 dd (9.5, 2) 97.9 3D 
2E,X 2.34 dd (13, 9.5) 44.3 
2Eeq 2.46 dd (13, 2) 
3E i i 70.7 
3E-CH3 1.93 S 27.0 2E, 4E 
4E 3.09 d (9) 76.8 
SE 4.65 m (overlap) 71.0 
6E 1.57 d (6) 17.7 
In FIG. 3, mithramycin-SA structure 4 gives indirect evi 
dence for the labile MTM structure 5, because its formation 
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from 5 is possible through the attack of water at the carbonyl 
adjacent to the methoxy group, followed by retro-aldol cleav 
age to yield mithramycin- SA structure 4 and hydroxyac 
etone. To prove the excision of carbon 3', two feeding experi 
ments using [1-13C]-acetate and [1,2-13C2]-acetate were 
performed. 
FIG. 5 shows the results of incorporation experiments with 
[1-l3C]-acetate and [1,2-13C2]-acetate on the mithramycin 
SK and mithramycin-SA produced from S. argillaecus 
M7W1, compared to the normal incorporation pattern found 
in mithramycin. In FIG. 5, R and R' are the deoxysaccharide 
chains shown in formulas (III) and (V). The comparison 
reveals that the former mithramycin carbon carbon 3' and 
carbons 3', 4' and 5' respectively, were excised during the 
formation of mithramycin-SK and mithramycin-SA, respec 
tively. It is believed that the [3-dicarbonyl constellation trig 
gers a Favorskii-like rearrangement, for which an 1,2-acyl 
shift induced by deprotonation of the central alcohol can be 
envisaged, followed by the addition of water on the resulting 
aldehyde and a consequent departure of formic acid. 
The oxidative rearrangement during the bio synthesis of 
MTM leads to an acetate incorporation pattern as shown in 
FIG. 5, wherein carbons 4' and 5' of the carbon 3 side chain 
stem from the starter unit, whereas carbons 1', 2', and 3' were 
once the end of the polyketide chain. If carbon 3' is lost, two 
intact acetate units facing each other from opposite directions 
should result. The results, also shown in FIG. 5, are consistent 
with these expectations and, thus, prove the loss of carbon 3'. 
Biological Activity 
The mithramycin SK has antitumor activity substantially 
higher than that of MTM and is particularly active against 
melanoma, leukemia and CNS cancer cells. Moreover, initial 
in vitro anticancer assays, pursued by the NCI (National 
Cancer Institute, Bethesda, Md.) against 60 human cancer 
cell lines, as well as an in vitro toxicity assay generated 
promising results in that mithramycin-SK showed an up to 
two orders of magnitude better antitumor activity and a two 
orders of magnitude lesser toxicity than the parent compound 
MTM itself. 
Table 3 shows IC5O values (pg/kg) of active extracts of the 
cancer cells. The experiment was performed by Biotecon, 
Berlin. It measures the uptake of sulforhodamin B (SRB), 
which is dependent on the cellular protein quantities, and can 
be performed in 96-well microtiter plates according to the 
protocol published by Boyd et al. (NCI). The SRB assay is a 
rapid and sensitive method to measure drug-induced cytotox 
icity. Brie?y, cells will be incubated with and without drug for 
72 hours (drugs will be added after 24 hours), ?xed with TCA 
(trichloroacetic acid), and stained for 30 minutes using a 
0.4% (w/v) SRB solution in 1 acetic acid. Cultures will then 
be rinsed with 1% acetic acid, residual wash solution will be 
removed and air-dried. Bound dye will be solubiliZed with 10 
mM unbuffered Tris base (pH 10.5) for 5 min., and the optical 
density (OD) will be measured with amicrotiter plate reader 
at 564 nm. (Skehan, P. et al., “New calorimetric cytotoxicity 
assay for anticancer-drug screening,” Journal of the National 
Cancer Institute, 1990. 82(13): p. 1107-1112). The data indi 
cate that mithramycin-SK was much more effective in reduc 
ing the growth of cancer cells in lung, breast and CNS cells 
when compared to other anti-cancer compounds at the same 
concentration. 
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TABLE 3 
Proliferation Inhibition Assays — Percent Growth in 48 Hours 
Mithramycin Concentration Lung Breast CNS 
Compound (molar) (NCI-H460) (MCF-7) (SF-268) 
Premithrarnycin 1 x 104"6 68 not tested 93 
Ar 
Premithrarnycin B 1 x 10’5 >100 >100 >100 
Mithramycin 1 x 10’5 12 12 not tested 
Mithrarnycin-SK 1>< 10*5 0.1 0.2 1 
Demycarosyl- 1 x 10’5 5 22 47 
Mithramycin-SK 
The cytotoxicity of Mithramycin-SK and demycarosyl 
mithramycin-SK were assessed in a panel of 60 cell lines 
using a sulforhodamine B assay. It is active against a variety 
of tumor cell lines in the concentration range of 10-5 to 10-8 
molar. Cell lines were inoculated into a series of 96-well 
microliter plates with varying seeding densities depending on 
the growth characteristics of the particular cell lines. Follow 
ing a 24 hour drug-free incubation, mithramycin-SK was 
added routinely at ?ve 10-fold dilutions with maximum con 
centration of 10.4 M. After 48 hours of drug exposure, the 
change in protein stain optical density allowed the inhibition 
of cell growth to be analyZed. 
Mithramycin-SK and demycarosyl-mithramycin-SK were 
also tested in a neutral red toxicity assay. In this experiment, 
non-tumorous mouse ?broblast cells were used (NIH 3T3). 
After 24 hours of incubation, Mithramycin-SK showed no 
toxicity even at 200 ug/mL, while the revealing antiprolifera 
tive activity in concentrations <1 ug/mL. 
Compilation of the average log(GI5O) values showed that 
both compounds were active, with mithramycin- SK (activity 
up to 9 times higher than that of MTM) being much more 
active than demycarosyl-mithramycin-SK (ca.25 times less 
active than MTM). Mithramycin-SK was particularly active 
against melanoma, leukemia, and CNS cancer cells (log 
(GI50) values of —7.64, —7.59, and —7.61, respectively). 
Given the increased activity observed for mithramycin-SK, a 
neutral red uptake analysis of squamous, melanoma, lung, 
and breast carcinomas was performed, which not only con 
?rmed the increased activity of mithramycin-SK as compared 
to MTM, but also showed an even more pronounced improve 
ment of activity (up to ca. 90 times better). In addition, tox 
icity assays using this same process and mouse 3T3 ?broblast 
(nontumor) cells showed that 2, with an IC5O value of 1.96>< 
10'5 M, is more than 1500-fold less toxic than MTM (IC5O 
values ranging from 1.29><10_8 to 3.45><10_9 M). Thus, mith 
ramycin-SK displays a signi?cantly improved therapeutic 
index, up to 4 orders of magnitude better when compared to 
its parent compound, MTM. The results are shown in Table 4. 
TABLE 4 
Antitumor Analysis Comparing Mithramycin (l), Mithramycin SK (2), 
and Demycarosyl-Mithrarnycin-SK (3). 
Composition with 2 Composition with 3 
Type ofCancer 1 2 AH AIF“ 3 AH AIF 
Average Log(GI5O) Values 
from Sulforhodarnine B Assay 
Leukemia (5)b —6.65 —7.59 0.94 8.7 —5.55 —1.10 0.08 
NSCLC (8)b —6.73 —7.37 0.64 4.4 —5.30 —1.43 0.04 
Colon (7)b —6.65 —7.32 0.67 4.7 —5.35 —1.30 0.05 
CNS (5)b —6.78 —7.61 0.83 6.8 —5.30 —1.48 0.03 
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TABLE 4-continued 
Antitumor Analysis Comparing Mithramycin (1), Mithramycin SK (2), 
and Demvcarosvl-Mithramvcin-SK (3). 
Composition with 2 Composition with 3 
Type ofCancer 1 2 A172 AIF“ 3 A13 AIF 
Melanoma(8)b —6.72 —7.64 0.92 8.3 —5.37 —1.35 0.04 
Ovarian(6)b —6.60 —7.53 0.93 8.5 —5.23 —1.37 0.04 
Renal(8)b —6.73 —7.29 0.56 3.6 —5.14 —1.59 0.03 
Prostrate(2)b —6.90 —7.48 0.58 3.8 —5.25 —1.65 0.02 
Breast (8)b —6.59 —5.89 —0.70 0.2 —5.15 —1.44 0.04 
Average Log(GI5O) Values 
from Neutral Red Assay 
Squamous carcinoma —5.04 —5.99 0.95 8.9 
Melanoma —5.05 —6.25 1.20 15.8 
Lung carcinoma —4.92 —6.88 1.96 91.2 
Breast carcinoma —4.95 —6.74 1.79 61.6 
“Activity improvement factor. This factor is equal to 10M“, Where x is the 
identifying value for compound 2 or 3. An AIF of 1.0 corresponds to no dif 
ference in activity. 
bThe number in parenthesis is the number of cell lines tested in each family. 
The data in Table 4 shows that mithramycin-SK (compound 
2) exhibits an activity that is up to 90 times higher than MTM 
(compound 1). 
Therapeutic Administration of the Mithramycin 
Derivatives 
The dosages or amounts of the compounds of the invention 
are large enough to produce the desired effect in the method 
by which delivery occurs. The dosage should not be so large 
as to cause adverse side effects, such as unwanted cross 
reactions, anaphylactic reactions, and the like. Generally, the 
dosage will vary with the age, condition, sex and extent of the 
disease in the subject and can be determined by one of skill in 
the art. The dosage can be adjusted by the individual physi 
cian based on the clinical condition of the subject involved. 
The dose, schedule of doses and route of administration may 
be varied. Doses and dosing regimens used form Mithramy 
cin provide guidance for dose and dosing regimens for Mith 
ramycin SK (see for example Trask and Sonhami, “Effect of 
Mithramycin on Widespread Painful Bone Metastases in 
Cancer of the Breast,” Cancer Treat. Rep, 63(11-12): 1835 
1838 (1979); and Conrad et al., “Mithramycin in the Treat 
ment ofSystemic Mastocytosis,”Ann. Intern. Med., 83(5): 65 
9-660 (1975)). For example, a single or multiple dose can be 
administered. In one embodiment, the dosages can be in 
ranges from 0.1 to 100 mg/kg, 0.1 to 90 mg/kg, 0.1 to 80 
mg/kg, 0.1 to 70 mg/kg, 0.1 to SOmg/kg, 0.1 to 20 mg/kg, 0.1 
to 10 mg/kg, 0.1 to 5 mg/kg or 0.1 to 1 mg/kg. In another 
embodiment, the compounds of the invention can also be 
administered for 5 days with a daily dose of0. 12 mg/kg. In yet 
another embodiment, a single dose of 1.0 mg/kg to 10 mg/kg 
can be administered. 
Any of the compounds of the invention can be used thera 
peutically in combination with a pharmaceutically acceptable 
carrier. Pharmaceutical carriers are known to those skilled in 
the art. These most typically would be standard carriers for 
administration of compositions to humans and non-humans, 
including solutions such as sterile water, saline, and buffered 
solutions at physiological pH. Other compounds will be 
administered according to standard procedures used by those 
skilled in the art. 
Any of the compounds of the invention intended for phar 
maceutical delivery may be formulated in a pharmaceutical 
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composition. Pharmaceutical compositions may include car 
riers, thickeners, diluents, buffers, preservatives, surface 
active agents and the like in addition to the molecule of 
choice. Pharmaceutical compositions may also include one or 
more active ingredients such as antimicrobial agents, antiin 
?ammatory agents, anesthetics, and the like. 
The compounds of the invention may be administered to 
the subject in a number of ways depending on whether local 
or systemic treatment is desired, and on the area to be treated. 
Thus, for example, a compound of the present invention can 
be administered as an ophthalmic solution and/ or ointment to 
the surface of the eye. Moreover, a compound can be admin 
istered to a subject vaginally, rectally, intranasally, orally, by 
inhalation, or parenterally, for example, by intradermal, sub 
cutaneous, intramuscular, intraperitoneal, intrarectal, intraar 
terial, intralymphatic, intravenous, intrathecal and intratra 
cheal routes. Parental administration, if used, is generally 
characterized by injection. Inj ectables can be prepared in 
conventional forms, either as liquid solutions or suspensions, 
solid forms suitable for solution or suspension in liquid prior 
to injection, or as emulsions. A more recently revised 
approach for parenteral administration involves use of a slow 
release or sustained release system such that a constant dos 
age is maintained. See, e.g., US. Pat. No. 3,610,795, whichis 
incorporated by reference herein. 
Preparations for parenteral administration include sterile 
aqueous or non-aqueous solutions, suspensions, and emul 
sions which may also contain buffers, diluents and other 
suitable additives. Examples of non-aqueous solvents are 
propylene glycol, polyethylene glycol, vegetable oils such as 
olive oil, and injectable organic esters such as ethyl oleate. 
Aqueous carriers include water, alcoholic/ aqueous solutions, 
emulsions or suspensions, including saline and buffered 
media. Parenteral vehicles include sodium chloride solution, 
Ringer’s dextrose, dextrose and sodium chloride, lactated 
Ringer’s, or ?xed oils. Intravenous vehicles include ?uid and 
nutrient replenishers, electrolyte replenishers (such as those 
based on Ringer’s dextrose), and the like. Preservatives and 
other additives may also be present such as, for example, 
antimicrobials, anti-oxidants, chelating agents, and inert 
gases and the like. 
Formulations for topical administration may include oint 
ments, lotions, creams, gels, drops, suppositories, sprays, 
liquids and powders. Conventional pharmaceutical carriers, 
aqueous, powder or oily bases, thickeners and the like may be 
necessary or desirable. 
Compositions for oral administration may include powders 
or granules, suspensions or solutions in water or non-aqueous 
media, capsules, sachets, or tablets. Thickeners, ?avorings, 
diluents, emulsi?ers, dispersing aids or binders may be desir 
able. 
In one embodiment, the compounds of the invention are 
administered to a subject comprising a human or an animal 
including, but not limited to, a mouse, dog, cat, horse, bovine 
or bovine and the like, that is in need of alleviation or ame 
lioration from a recognized medical condition. 
The present invention also provides a method of treating 
Paget’s Disease in a subject diagnosed with Paget’s Disease, 
comprising administering to the subject an effective amount 
of a compound of the invention, whereby the compound treats 
the Paget’s Disease in the subject. The subject can be a mam 
mal, preferably a human, and the compound is administered 
parenterally. 
Further provided by the present invention is a method of 
treating hypercalcemia in a subject diagnosed with hypercal 
cemia, comprising administering to the subject an effective 
amount of a compound of the invention in a pharmaceutically 
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acceptable carrier, whereby the compound treats hypercalce 
mia in the subject. The subject can be a mammal, preferably 
a human, and the compound is administered parenterally. 
The present invention also provides a method of providing 
neuroprotection in subject diagnosed With neurological dis 
eases, the method comprising the step of administering to the 
subject an effective amount of a compound of the invention in 
a pharmaceutically acceptable carrier, Whereby the com 
pound provides neuroprotection in the subject. The subject 
can be a mammal, preferably a human, and the compound is 
administered parenterally. 
The present invention also provides a method of providing 
neuroprotection in subject diagnosed With neurological dis 
eases, the method comprising the step of administering to the 
24 
The compounds of the invention can be useful as a bio 
chemical tool. For example, the compounds can be useful to 
block the c-Src (and other Spl-dependent enzymes) expres 
sion in osteoclast or other cells. 
It Will be apparent to those skilled in the art that various 
modi?cations and variations can be made in the present 
invention Without departing from the scope or spirit of the 
invention. Other embodiments of the invention Will be appar 
ent to those skilled in the art from consideration of the speci 
?cation and practice of the invention disclosed herein. It is 
intended that the speci?cation and examples be considered as 
exemplary only, With a true scope and spirit of the invention 
being indicated by the folloWing claims. 
This invention is not limited to speci?c synthetic methods, 
subject an effective amount of a compound of the invention in 15 speci?c compositions, or to particular formulations, as such 
a pharmaceutically acceptable carrier, Whereby the com- may, of course, vary. It is also to be understood that the 
pound provides neuroprotection in the subject. The subject terminology used herein is for the purpose of describing 
can be a mammal, preferably a human, and the compound is particular embodiments only and is not intended to be limit 
administered parenterally. ing. 
SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS: 1 
<211> LENGTH: 5975 
<212> TYPE: DNA 
<2l3> ORGANISM: Streptomyces argillaceus 
<4oo> SEQUENCE: 1 
ggatcctcgt ccgtctcgac caccaggtag cggctcagcg cccggtagaa acggccgccc 60 
tcctcggact gcacggcgtc gtagaggatc tgctccggcc gggccgcgag cacctggtcc 120 
aggaacctgg gccgctgttc gggggggaga tgagcgtggt cgtcggggac gcactggacg 180 
gtcggggcca gctcgatgag gtcgacgtag cccggttccg ggtgggcgcg cgccaggacg 240 
tggaggacgc cgtcgatccg cttggccagg aacgccacca ccccggtgcc gcgcgggctg 300 
agcagcggct gggtccaccc cttgacttcg cggttgccgg cctccacaga cacggcgacg 360 
atcgcgaagt gccgtccact ggtgtggcgt atctcgtccg tgtcgcggac ccagccgtcc 420 
acggaggtca gcgggacgag ctgcgcggcg acctcgctgc gcgccctgag cccgttgaac 480 
cagcgcagca gctcgggcag ggtgtgcgcg gcgggggcct gcgcggacag ggaggcggtc 540 
agggcggcca cggccgcccc gcgggaaccg tcggtcgtga ctccctcgag ggaaccgtcc 600 
ggcggggcga cggggaggca ggccaggacc gtccgagtgt ccatgttgac caggtccggg 660 
acgccgagca gccggcggac ctgaccgagg gtcagccagc ggtagtcctc gtgctcgggc 720 
acgtcgccga cggcctcgac gacgagattg cggttgcgtt tgcggaagaa ccaggaaccg 780 
tgctcggact ggagcacgtc gaccagcggc cggcccttgc cggggtccgt gaagtactcc 840 
aggtaccgca cggcgctgcc ctcgtgcacg cccgtgtagt tgctgcgggt ggcctgcacc 900 
gtgggcgaca actggagtcc ctcggcgttg ccgggctcgg ccttcgcctg catcaggcag 960 
tgcaggacac cgtcgaactc cttgaccagg atgccgagga aacccacttc cggctggtgc 1020 
atgatcggct gggaccagga gacggggtcc gggccctcgg agcgagcccg cagcccttcg 1080 
acggtgaaga agcggccgct gtcgtgcgcc agattcccgg tgaccgggtg gaagccccag 1140 
cgctggagct cggcgaaggg gatgcgcctc acgtccatcc ggatggcctt gcggcgctcc 1200 
tcgaaccagt cgtggacacc acccagggac agcagtccgc tgtcggccgc cgccgattcg 1260 





